

Oral Iron Therapy: Efficacy, Adherence, and Innovations

Tomas Eriksson*

Department of Clinical Trial Design & Biostatistics, Lund University, Lund 221 00, Sweden

Introduction

Oral iron supplementation stands as a fundamental approach in the management of iron deficiency anemia, demonstrating considerable success in restoring hemoglobin levels and replenishing iron stores across a wide spectrum of patient demographics [1]. The selection of appropriate iron formulations and precise dosages is paramount to optimizing absorption and minimizing gastrointestinal adverse effects, which in turn significantly enhances patient adherence and the overall effectiveness of treatment [1].

The specific choice of oral iron formulation profoundly influences both the efficacy and the tolerability of treatment in patients experiencing anemia [2]. Ferrous bisglycinate, a chelated form of iron, is frequently observed to offer improved absorption characteristics and a reduction in gastrointestinal discomfort when contrasted with conventional ferrous salts, thereby fostering better patient compliance and more consistent increases in hemoglobin levels [2].

Patient adherence to oral iron therapy represents a critical determinant for the successful resolution of iron deficiency anemia [3]. A thorough understanding of the various barriers that patients encounter, such as the occurrence of side effects and the complexity of prescribed dosing regimens, coupled with the implementation of targeted supportive interventions, including comprehensive patient education and the provision of alternative formulations, can substantially bolster compliance and improve clinical outcomes [3].

The gastrointestinal tolerability associated with oral iron supplements continues to pose a notable challenge in clinical practice [4]. Ongoing research and development are focused on exploring novel formulations and co-administration strategies involving agents that can enhance iron absorption or mitigate adverse effects, with the overarching goal of improving the patient experience and augmenting the overall effectiveness of oral iron treatment regimens [4].

Iron deficiency anemia that arises during pregnancy necessitates a meticulous and carefully managed approach with oral iron supplementation [5]. Clinical studies consistently affirm that oral iron therapy is generally considered both safe and effective in elevating maternal hemoglobin concentrations and improving iron status, although rigorous monitoring for potential side effects and ensuring patient adherence remain indispensable aspects of care [5].

The comparative efficacy of various oral iron salts utilized in the treatment of iron deficiency anemia exhibits significant variation [6]. Commonly employed iron salts include ferrous sulfate, ferrous fumarate, and ferrous gluconate, with their respective absorption rates being susceptible to influencing factors such as gastric acidity levels and the presence of dietary inhibitors [6].

Recent scientific inquiry is actively engaged in elucidating these intricate nuances to refine and optimize the dosing strategies employed in iron therapy [6]. The

use of oral iron in individuals diagnosed with inflammatory bowel disease (IBD) introduces a unique set of challenges, primarily stemming from the potential for symptom exacerbation [7].

Nevertheless, through the judicious selection of specific oral iron formulations and the implementation of carefully controlled dosing schedules, it is possible to effectively and safely manage anemia in IBD patients, often observing improved tolerability compared to parenteral iron administration routes [7].

Iron absorption from orally administered supplements is subject to the influence of a multitude of factors, encompassing the timing of intake relative to food consumption, concurrent medication use, and the inherent characteristics of individual patients [8]. A comprehensive understanding of these complex interactions is indispensable for the strategic optimization of oral iron therapy's effectiveness and for the successful attainment of therapeutic objectives in individuals suffering from anemia [8].

Furthermore, the incorporation of ascorbic acid, commonly known as vitamin C, as an adjunct to oral iron therapy has been demonstrably shown to potentiate iron absorption and enhance the hemoglobin response in anemic populations [9]. This observed synergistic effect underscores the critical importance of considering complementary therapeutic strategies to maximize the clinical benefits derived from oral iron administration [9].

Description

Oral iron supplementation is recognized as a primary strategy for addressing iron deficiency anemia, showing significant effectiveness in raising hemoglobin levels and improving iron reserves in various patient groups [1]. Crucial to optimizing treatment is the careful selection of iron formulations and dosages to enhance absorption and reduce gastrointestinal side effects, thereby improving patient compliance and treatment outcomes [1].

The selection of an oral iron formulation critically affects treatment efficacy and tolerability in anemic individuals [2]. Ferrous bisglycinate, a chelated iron form, typically demonstrates superior absorption and fewer gastrointestinal side effects compared to traditional ferrous salts, leading to enhanced compliance and sustained hemoglobin improvements [2].

Adherence to oral iron therapy is a pivotal factor for successful management of iron deficiency anemia [3]. Identifying patient barriers, such as side effects and complex dosing schedules, and implementing support strategies like patient education and alternative formulations can significantly boost compliance and clinical results [3].

The gastrointestinal tolerability of oral iron supplements remains a substantial hurdle [4]. New formulations and the concurrent use of agents that improve absorption

or mitigate side effects are being investigated to enhance the patient experience and the overall effectiveness of oral iron treatment [4].

Iron deficiency anemia during pregnancy requires careful management with oral iron [5]. Studies confirm that oral iron supplementation is generally safe and effective for improving maternal hemoglobin levels and iron status, though close monitoring for side effects and adherence is vital [5].

The efficacy of different oral iron salts in treating iron deficiency anemia varies [6]. Common iron salts include ferrous sulfate, ferrous fumarate, and ferrous gluconate, with absorption influenced by factors like gastric pH and dietary inhibitors [6].

Recent research aims to understand these variations to optimize dosing strategies [6]. The application of oral iron in patients with inflammatory bowel disease (IBD) presents distinct challenges due to the potential for symptom exacerbation [7].

However, carefully chosen oral iron formulations and controlled dosing can effectively and safely manage anemia in IBD patients, often with better tolerance than parenteral iron [7].

Iron absorption from oral supplements is affected by numerous factors, including food intake, medications, and individual patient characteristics [8]. Understanding these interactions is essential for optimizing oral iron therapy effectiveness and achieving therapeutic goals in anemic individuals [8].

Moreover, the use of ascorbic acid (vitamin C) alongside oral iron therapy has been shown to enhance iron absorption and improve hemoglobin response in anemic patients [9]. This synergistic effect highlights the importance of considering complementary strategies to maximize the benefits of oral iron [9].

Conclusion

Oral iron supplementation is a key treatment for iron deficiency anemia, effective in restoring hemoglobin and iron stores. Choosing the right formulation and dosage is crucial for optimal absorption and minimizing side effects, which improves patient adherence. Ferrous bisglycinate is noted for better absorption and tolerability than ferrous salts. Patient adherence is critical, and barriers like side effects need to be addressed through education and alternative formulations. Gastrointestinal tolerability remains a challenge, leading to research into new formulations and adjunct therapies. Oral iron is safe and effective in pregnancy, but requires monitoring. Efficacy varies among iron salts, with absorption influenced by various factors. In inflammatory bowel disease, oral iron can be managed safely with careful selection and dosing. Factors like diet and medications impact iron absorption, necessitating an understanding of these interactions for effective therapy. Vitamin C can enhance iron absorption and hemoglobin response when used adjunctively with oral iron.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Todorovic V, Simic T, Jovanovic M. "Oral Iron Supplementation in the Management of Iron Deficiency Anemia: A Review." *J Clin Med* 12 (2023):12(15):4936.
2. Uusitalo K, Kautiainen H, Voutilainen S. "Efficacy and Tolerability of Ferrous Bisglycinate in Anemia Treatment: A Systematic Review and Meta-Analysis." *Nutrients* 14 (2022):14(17):3583.
3. Gordeuk VR, Delgado-Lamas G, Viteri FE. "Factors Affecting Adherence to Oral Iron Therapy in Patients with Iron Deficiency Anemia." *Blood Adv* 5 (2021):5(18):3750-3757.
4. Bohmer G, Reid P, Van der Merwe S. "Improving Oral Iron Therapy: Addressing the Challenge of Gastrointestinal Side Effects." *World J Gastroenterol* 26 (2020):26(26):3528-3537.
5. Acharya S, Garg P, Chauhan N. "Oral Iron Supplementation for Iron Deficiency Anemia in Pregnancy: A Randomized Controlled Trial." *Am J Obstet Gynecol* 228 (2023):228(4):S985.
6. Yuan W, Wang X, Li Y. "Comparative Efficacy of Different Oral Iron Salts in the Treatment of Iron Deficiency Anemia." *Clin Ther* 44 (2022):44(11):1493-1502.e2.
7. Garrido R, Gomes A, Ribeiro N. "Oral Iron Supplementation in Patients with Inflammatory Bowel Disease: A Review of Efficacy and Safety." *J Crohns Colitis* 17 (2023):17(5):737-746.
8. Riedel H, Schönfeld P, Meyer S. "Factors Influencing Oral Iron Absorption: Implications for Treatment Strategies." *Anemia* 2022 (2022):2022:1957541.
9. Luo Y, Zhang X, Li Z. "Effect of Ascorbic Acid on Oral Iron Absorption and Hemoglobin Response in Anemia: A Meta-Analysis." *J Nutr Sci* 10 (2021):10:e42.
10. Gazzaruso S, De Pergola G, Baralis G. "Monitoring Iron Status and Treatment Response in Patients with Iron Deficiency Anemia." *Int J Lab Hematol* 45 (2023):45(1):17-25.

How to cite this article: Eriksson, Tomas. "Oral Iron Therapy: Efficacy, Adherence, and Innovations." *J Clin Res* 09 (2025):365.

***Address for Correspondence:** Tomas, Eriksson, Department of Clinical Trial Design & Biostatistics, Lund University, Lund 221 00, Sweden, E-mail: tomas.eriksson@lu.se

Copyright: © 2025 Eriksson T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Received: 01-Dec-2025, Manuscript No. jcre-26-187235; **Editor assigned:** 03-Dec-2025, PreQC No. P-187235; **Reviewed:** 17-Dec-2025, QC No. Q-187235; **Revised:** 22-Dec-2025, Manuscript No. R-187235; **Published:** 29-Dec-2025, DOI: 10.37421/2795-6172.2025.9.365